Whole-genome landscape of adult T-cell leukemia/lymphoma.
Animals
Ataxin-1
/ genetics
Biomarkers, Tumor
/ genetics
DNA Copy Number Variations
Female
Gene Expression Regulation, Neoplastic
Genome, Human
Humans
Leukemia-Lymphoma, Adult T-Cell
/ genetics
Mice
Mice, Inbred C57BL
Mutation
Prognosis
Proto-Oncogene Proteins c-rel
/ genetics
Repressor Proteins
/ genetics
Survival Rate
Exome Sequencing
Journal
Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509
Informations de publication
Date de publication:
17 02 2022
17 02 2022
Historique:
received:
05
08
2021
accepted:
11
10
2021
pubmed:
26
10
2021
medline:
1
3
2022
entrez:
25
10
2021
Statut:
ppublish
Résumé
Adult T-cell leukemia/lymphoma (ATL) is an aggressive neoplasm immunophenotypically resembling regulatory T cells, associated with human T-cell leukemia virus type-1. Here, we performed whole-genome sequencing (WGS) of 150 ATL cases to reveal the overarching landscape of genetic alterations in ATL. We discovered frequent (33%) loss-of-function alterations preferentially targeting the CIC long isoform, which were overlooked by previous exome-centric studies of various cancer types. Long but not short isoform-specific inactivation of Cic selectively increased CD4+CD25+Foxp3+ T cells in vivo. We also found recurrent (13%) 3'-truncations of REL, which induce transcriptional upregulation and generate gain-of-function proteins. More importantly, REL truncations are also common in diffuse large B-cell lymphoma, especially in germinal center B-cell-like subtype (12%). In the non-coding genome, we identified recurrent mutations in regulatory elements, particularly splice sites, of several driver genes. In addition, we characterized the different mutational processes operative in clustered hypermutation sites within and outside immunoglobulin/T-cell receptor genes and identified the mutational enrichment at the binding sites of host and viral transcription factors, suggesting their activities in ATL. By combining the analyses for coding and noncoding mutations, structural variations, and copy number alterations, we discovered 56 recurrently altered driver genes, including 11 novel ones. Finally, ATL cases were classified into 2 molecular groups with distinct clinical and genetic characteristics based on the driver alteration profile. Our findings not only help to improve diagnostic and therapeutic strategies in ATL, but also provide insights into T-cell biology and have implications for genome-wide cancer driver discovery.
Identifiants
pubmed: 34695199
pii: S0006-4971(21)01784-5
doi: 10.1182/blood.2021013568
pmc: PMC8854674
doi:
Substances chimiques
ATXN1 protein, human
0
Ataxin-1
0
Biomarkers, Tumor
0
CIC protein, human
0
Proto-Oncogene Proteins c-rel
0
REL protein, human
0
Repressor Proteins
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
967-982Subventions
Organisme : NCI NIH HHS
ID : R01 CA223232
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022 by The American Society of Hematology.
Références
Blood. 2018 Oct 4;132(14):1507-1518
pubmed: 30104217
Nat Genet. 2017 Jan;49(1):87-96
pubmed: 27869830
Nat Genet. 2020 Mar;52(3):306-319
pubmed: 32024998
J Clin Oncol. 2019 Mar 10;37(8):677-687
pubmed: 30657736
Cell. 2002 Sep 20;110(6):673-87
pubmed: 12297042
Science. 2018 Nov 9;362(6415):694-699
pubmed: 30409884
J Clin Oncol. 2009 Jan 20;27(3):453-9
pubmed: 19064971
Nat Genet. 2013 Oct;45(10):1113-20
pubmed: 24071849
Nat Commun. 2020 Feb 5;11(1):734
pubmed: 32024818
Blood. 2003 May 1;101(9):3681-6
pubmed: 12511414
Lancet Oncol. 2014 Oct;15(11):e517-26
pubmed: 25281470
Cancer Discov. 2018 Dec;8(12):1614-1631
pubmed: 30266814
Cell. 2018 Jul 26;174(3):758-769.e9
pubmed: 30033370
Cell Death Dis. 2021 Apr 28;12(5):419
pubmed: 33911074
Cancer Cell. 2018 Aug 13;34(2):286-297.e10
pubmed: 30057145
Blood. 2020 Apr 23;135(17):1467-1471
pubmed: 31961925
Nat Commun. 2017 Jul 12;8:16037
pubmed: 28855737
Genes Cancer. 2011 Jul;2(7):695-711
pubmed: 22207895
N Engl J Med. 2018 Apr 12;378(15):1396-1407
pubmed: 29641966
Nature. 2014 Jan 23;505(7484):495-501
pubmed: 24390350
Trends Genet. 2020 Dec;36(12):936-950
pubmed: 32873422
Blood. 2018 Oct 18;132(16):1695-1702
pubmed: 30126979
Nat Rev Cancer. 2007 Apr;7(4):270-80
pubmed: 17384582
Nature. 2020 Feb;578(7793):82-93
pubmed: 32025007
Nat Commun. 2018 Oct 1;9(1):4001
pubmed: 30275490
Blood. 2020 Jun 4;135(23):2023-2032
pubmed: 32160278
Nature. 2020 Feb;578(7793):94-101
pubmed: 32025018
Leukemia. 2015 May;29(5):1177-85
pubmed: 25428260
Science. 2013 Oct 04;342(6154):1235587
pubmed: 24092746
Nature. 2009 Jun 4;459(7247):717-21
pubmed: 19412164
Nature. 2020 Feb;578(7793):102-111
pubmed: 32025015
Oncogene. 1991 Jul;6(7):1235-41
pubmed: 1650444
Nat Commun. 2015 Dec 07;6:8866
pubmed: 26638776
Nucleic Acids Res. 2015 Sep 30;43(17):8123-34
pubmed: 26304545
J Cell Sci. 2012 Mar 15;125(Pt 6):1383-91
pubmed: 22526417
Nature. 2016 Apr 14;532(7598):264-7
pubmed: 27075101
Nat Genet. 2015 Nov;47(11):1304-15
pubmed: 26437031
Proc Natl Acad Sci U S A. 2012 Dec 26;109(52):21426-31
pubmed: 23213202
Neuron. 2018 Mar 21;97(6):1235-1243.e5
pubmed: 29526553
Am J Hematol. 2016 Sep;91(9):923-30
pubmed: 27312795
Nature. 2015 Oct 22;526(7574):519-24
pubmed: 26200345
Nature. 2016 May 23;534(7607):402-6
pubmed: 27281199
Cell. 2006 Dec 29;127(7):1335-47
pubmed: 17190598
N Engl J Med. 2015 Jun 25;372(26):2481-98
pubmed: 26061751
Leukemia. 2019 Dec;33(12):2867-2883
pubmed: 31092896
Cell. 2017 Nov 16;171(5):1029-1041.e21
pubmed: 29056346
Nat Rev Immunol. 2013 Apr;13(4):257-69
pubmed: 23524462